Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed)
The summary for the Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed): The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms as delivery vehicles for cancer treatment and to complement or synergize with current therapies. This FOA will accept basic mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants responding to this FOA must address both the microbial and the tumor aspects of microbial-based cancer therapy. Complex microbial-tumor interactions are best addressed with a multidisciplinary approach. The purpose of this FOA is to encourage basic or applied, multidisciplinary research collaborations between investigators from areas relevant to microbial-based cancer therapy, such as microbiology, oncology, immunology, and cellular and molecular cancer biology. The proposed projects should be state of the art and aim to advance pre-clinical development of novel microbial-based anticancer therapeutic agents, or study the complex biology involved in the interplay of microbe-tumor-immune system. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and should apply an integrative approach to increase our understanding of biological, or translational aspects of microbial-based anticancer therapeutic agents.
Federal Grant Title: | Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-19-194 |
Type of Funding: | Grant |
CFDA Numbers: | 93.395, 93.396 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | May 7th, 2022 |
Original Application Deadline: | May 7th, 2022 |
Posted Date: | February 22nd, 2019 |
Creation Date: | February 22nd, 2019 |
Archive Date: | June 12th, 2022 |
Total Program Funding: | |
Maximum Federal Grant Award: | $200,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | February 22nd, 2019 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PAR-19-194.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
- • Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...
- • Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...
- • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...
- • Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)
- • Breast and Prostate Cancer Data Quality and Patterns of Care Study
- • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults
- • National Cooperative Drug Discovery Groups for Cancer
- More Grants from the National Institutes of Health
- • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...
- • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional)
- • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...